72-Hour in vivo evaluation of nitric oxide generating artificial lung gas exchange fibers in sheep
Source abstract
Abstract
The large, densely packed artificial surface area of artificial lungs results in rapid clotting and device failure. Surface generated nitric oxide (NO) can be used to reduce platelet activation and coagulation on gas exchange fibers, while not inducing patient bleeding due to its short half-life in blood. To generate NO, artificial lungs can be manufactured with PDMS hollow fibers embedded with copper nanoparticles (Cu NP) and supplied with an infusion of the NO donor S-nitroso-N-acetyl-penicillamine (SNAP). The SNAP reacts with Cu NP to generate NO. This study investigates clot formation and gas exchange performance of artificial lungs with either NO-generating Cu-PDMS or standard polymethylpentene (PMP) fibers. One miniature artificial lung (MAL) made with 10 wt% Cu-PDMS hollow fibers and one PMP control MAL were attached to sheep in parallel in a veno-venous extracorporeal membrane oxygenation circuit (n = 8). Blood flow through each device was set at 300 mL/min, and each device received a SNAP infusion of 0.12 μmol/min. The ACT was between 110 and 180 s in all cases. Blood flow resistance was calculated as a measure of clot formation on the fiber bundle. Gas exchange experiments comparing the two groups were conducted every 24 h at blood flow rates of 300 and 600 mL/min. Devices were removed once the resistance reached 3x baseline (failure) or following 72 h. All devices were imaged using scanning electron microscopy (SEM) at the inlet, outlet, and middle of the fiber bundle. The Cu-PDMS NO generating MALs had a significantly smaller increase in resistance compared to the control devices. Resistance rose from 26 ± 8 and 23 ± 5 in the control and Cu-PDMS devices, respectively, to 35 ± 8 mmHg/(mL/min) and 72 ± 23 mmHg/(mL/min) at the end of each experiment. The resistance and SEM imaging of fiber surfaces demonstrate lower clot formation on Cu-PDMS fibers. Although not statistically significant, oxygen transfer for the Cu-PDMS MALs was 13.3% less than the control at 600 mL/min blood flow rate. Future in vivo studies with larger Cu-PDMS devices are needed to define gas exchange capabilities and anticoagulant activity over a long-term study at clinically relevant ACTs. STATEMENT OF SIGNIFICANCE: In artificial lungs, the large, densely-packed blood contacting surface area of the hollow fiber bundle is critical for gas exchange but also creates rapid, surface-generated clot requiring significant anticoagulation. Monitoring of anticoagulation, thrombosis, and resultant complications has kept permanent respiratory support from becoming a clinical reality. In this study, we use a hollow fiber material that generates nitric oxide (NO) to prevent platelet activation at the blood contacting surface. This material is tested in vivo in a miniature artificial lung and compared against the clinical standard. Results indicated significantly reduced clot formation. Surface-focused anticoagulation like this should reduce complication rates and allow for permanent respiratory support by extending the functional lifespan of artificial lungs and can further be applied to other medical devices.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Mechanical Circulatory Support Devices · Neonatal Respiratory Health Research · Cardiac Arrest and Resuscitation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (47)
Show source-provided references
1. The catastrophe revisited: blood compatibility in the 21st century10.1016/j.biomaterials.2007.07.035 ↗
2. Extracorporeal circulatory systems as a bridge to lung transplantation at remote transplant centers10.1016/j.athoracsur.2010.09.005 ↗
3. Bridge to lung transplantation with the novel pumpless interventional lung assist device NovaLung10.1016/j.jtcvs.2005.10.050 ↗
4. Bridge to thoracic organ transplantation in patients with pulmonary arterial hypertension using a pumpless lung assist device10.1111/j.1600-6143.2009.02549.x ↗
5. T.M. Maul, P.M. Massicotte, P.D. Wearden, ECMO Biocompatibility: surface coatings, anticoagulation, and coagulation monitoring, in: Extracorpor. Membr. Oxyg. – Adv. Ther., 2016, pp. 27–56.10.5772/63888 ↗
6. First experience with a paracorporeal artificial lung in humans10.1097/MAT.0b013e31819740a0 ↗
7. Hemorrhagic complications of anticoagulant treatment10.1378/chest.119.1_suppl.108S ↗
8. Association of bleeding and thrombosis with outcome in Extracorporeal Life Support10.1097/PCC.0000000000000317 ↗
9. Bleeding, transfusion, and mortality on extracorporeal life support: ECLS working group on thrombosis and hemostasis10.1016/j.athoracsur.2015.07.046 ↗
10. Mechanical ventilation management during extracoporeal membrane oxygenation for acute respiratory distress syndrome: a retrospective international multicenter study
11. 2-Hydroxy-5-nitrobenzyl as a diazeniumdiolate protecting group: application in no-releasing polymers with enhanced biocompatibility10.1021/ol801883f ↗
12. Nitric oxide-generating silicone as a blood-contacting biomaterial10.1097/MAT.0b013e31823b9692 ↗
13. Fabrication and in vivo thrombogenicity testing of nitric oxide generating artificial lungs10.1002/jbm.a.34655 ↗
14. Multi-modal, surface-focused anticoagulation using poly-2-methoxyethylacrylate polymer grafts and surface nitric oxide release10.1002/admi.201400012 ↗
15. Long-term nitric oxide release and elevated temperature stability with S-nitroso-N-acetylpenicillamine (SNAP)-doped Elast-eon E2As polymer10.1016/j.biomaterials.2013.05.063 ↗
16. Improved hemocompatibility of silicone rubber extracorporeal tubing via solvent swelling-impregnation of S-nitroso-N-acetylpenicillamine (SNAP) and evaluation in rabbit thrombogenicity model10.1016/j.actbio.2016.04.025 ↗
17. Polymers incorporating nitric oxide releasing/generating substances for improved biocompatibility of blood-contacting medical devices10.1016/j.biomaterials.2004.06.006 ↗
18. Attenuation of thrombosis and bacterial infection using dual function nitric oxide releasing central venous catheters in a 9 day rabbit model10.1016/j.actbio.2016.08.009 ↗
19. Estimation of nitric oxide production and reaction rates in tissue by use of mathematical model
20. The hemocompatibility of a nitric oxide generating polymer that catalyzes S-nitrosothiol decomposition in an extracorporeal circulation model10.1016/j.biomaterials.2011.03.036 ↗
21. Nitric oxide-releasing biopolymers inhibit thrombus formation in a sheep model of arteriovenous bridge grafts10.1016/j.jvs.2004.07.007 ↗
22. Hemocompatibility comparison of biomedical grade polymers using rabbit thrombogenicity model for preparing nonthrombogenic nitric oxide releasing surfaces10.1039/C3TB21771J ↗
23. Fourteen day in vivo testing of a compliant thoracic artificial lung10.1097/MAT.0000000000000627 ↗
24. Hemodynamic and gas transfer properties of a compliant thoracic artificial lung10.1097/01.mat.0000169707.72242.8f ↗
25. Noninvasive measurements of cardiac output in sheep: an improved thermometry method10.1016/S1350-4533(97)00021-0 ↗
26. Lack of a critical cardiac output and critical systemic oxygen delivery during low cardiac output in the third trimester in the pregnant sheep10.1016/S0002-9378(96)70279-X ↗
27. Rapid method for the estimation of plasma haemoglobin levels10.1136/jcp.21.1.110 ↗
28. Seven-day artificial lung testing in an in-parallel configuration10.1016/j.athoracsur.2007.03.016 ↗
29. Thirty-day in-parallel artificial lung testing in sheep10.1016/j.athoracsur.2007.05.051 ↗
30. Survey of the status of copper, interacting minerals, and vitamin E levels in the livers of sheep in Ontario
31. The effects of nitric oxide on coagulation during simulated extracorporeal membrane oxygenation10.1051/ject/2000324214 ↗
32. Nitric oxide releasing material adsorbs more fibrinogen10.1002/jbm.a.34627 ↗
33. The attenuation of platelet and monocyte activation in a rabbit model of extracorporeal circulation by a nitric oxide releasing polymer10.1016/j.biomaterials.2009.12.028 ↗
34. Compact cross-flow tubular oxygenators
35. Testing of an intrathoracic artificial lung in a pig model10.1097/00002480-199609000-00059 ↗
36. Copper biochemistry and molecular biology10.1093/ajcn/63.5.797 ↗
37. Acute toxicological effects of copper nanoparticles in vivo10.1016/j.toxlet.2005.10.003 ↗
38. Safety of using copper oxide in medical devices and consumer products
39. Manifestations of copper excess10.1093/ajcn/67.5.1069S ↗
40. Serum copper, zinc, and calcium concentrations in lice-infested sheep10.1385/BTER:88:1:87 ↗
41. The effect of copper excess on iron metabolism in sheep10.1042/bj1700137 ↗
42. Copper toxicity in sheep
43. Serum copper and haematological values of sheep of different physiological stages in the dry and wet seasons of central trinidad10.1155/2014/972074 ↗
44. Significantly reduced adsorption and activation of blood components in a membrane oxygenator system coated with crosslinkable zwitterionic copolymer10.1016/j.actbio.2016.02.036 ↗
45. A new phosphorylcholine-coated polymethylpentene oxygenator for extracorporeal membrane oxygenation: a preliminary experience
46. In vivo testing of a novel blood pump for short-term extracorporeal life support10.1016/j.athoracsur.2014.04.027 ↗
47. Effect of varying nitric oxide release to prevent platelet consumption and preserve platelet function in an in vivo model of extracorporeal circulation10.1177/0267659107080877 ↗